Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI South Korea ETF (EWY) vs Moderna, Inc. (MRNA) Price & Performance

iShares MSCI South Korea ETFTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

iShares MSCI South Korea ETF vs Moderna, Inc. — how do they compare? iShares MSCI South Korea ETF trades at $163.51, while Moderna, Inc. trades at $64.15 (market cap $27.09B). Which is the better fit depends on your goals.

EWYMRNA
Sector
Broad Market / FactorHealth
52-Week High
$219.20$81.80
52-Week Low
$70.65$22.36
Market Cap
$27.09B
Enterprise Value
$23.19B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI South Korea ETF

EWY is trading at $163.67, down 7.52% with significant volatility driven by its heavy concentration in South Korean semiconductor giants Samsung and SK Hynix. The ETF has entered bear market territory, reflecting global tech sector pressures and foreign investor selling. Technical indicators show bearish momentum with RSI near oversold levels at 28, while support sits at $157. Recent news highlights the Kospi Index's 21% decline from YTD highs, creating both risk and potential opportunity.

The outlook remains challenged by semiconductor cycle volatility and concentrated exposure, but long-term AI demand fundamentals provide potential upside. Key risks include single-stock concentration, foreign capital flows, and global tech sentiment shifts. Investors should weigh near-term volatility against structural semiconductor growth drivers.

Moderna, Inc.

Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.

Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI South Korea ETF

EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.

Read more on EWY

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA